Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Show more

Location: 47 Thorndike Street, Cambridge, MA, 02141, United States | Website: https://www.leaptx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

12.01M

52 Wk Range

$0.22 - $4.79

Previous Close

$0.29

Open

$0.28

Volume

337,363

Day Range

$0.27 - $0.30

Enterprise Value

-6.078M

Cash

18.13M

Avg Qtr Burn

-15.02M

Insider Ownership

16.21%

Institutional Own.

22.06%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sirexatamab (DKN-01) + Bevacizumab and Chemotherapy Details Advanced microsatellite stable colorectal cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) +/- Paclitaxel Details Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) + Pembrolizumab Details Cancer, Endometrial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) +/- Docetaxel Details Prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FL-301 Details Cancer, Pancreatic cancer, Gastric cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirexatamab (DKN-01) + Tislelizumab +/- CAPOX Details Gastroesophageal junction tumors, Cancer, Gastric cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.